Taisho Pharmaceutical Co., Ltd.

Meiji Seika Kaisha, Ltd.

Madoka Kawamura

Masato Kashimura

Haruhisa Ogita

Yuji Ito

Hiroaki Tanaka

Tsuyoshi Shibata

Kazuaki Suzuki

Naoya Ono

Toshifumi Asaka

Eiki Shitara

Tomohiro Sugimoto

Yoshinori Sekiguchi

Tomoaki Miura

Kiyoshi Takayama

Hajime Asanuma

Takahiro Oi

Tetsuya Yabuuchi

Makoto Hamada

Tetsuo Takayama

Yusuke Oka

Shoichi Kuroda

Kenichi Kanemoto

Dai Kubota

Yohei Kobashi

Fumito Uneuchi

Kanako Yamamoto

Ken Chikauchi

Akira Manaka

Naoki Sasamoto

Jun Kurosaka

Daisuke Wakasugi

Takeshi Koami

Naoki Miyakoshi

Kosuke Kanuma

Tomohiro Ozawa

Rie Nishikawa

Ayako Bohno

Kosuke Funayama

The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme. (in formula [I] above, the structure represented by formula [II] below: represents any of the structures represented by formula group [III] below: R, R, R, and Rindependently represent a hydrogen atom, a fluorine atom, methyl, or the like, Rrepresents any of the structures represented by formula group [IV]: 

Pyridine compound substituted with azole

PROBLEM To provide a novel compound, a pharmaceutically acceptable salt or a hydrate thereof useful for preventing or treating for depression, anxiety disorders (such as generalized anxiety disorder, posttraumatic stress disorder, panic disorder, obsessive-compulsive disorder or social anxiety disorder), attention deficit disorder, mania, manic-depressive illness, schizophrenia, mood disorders, stress, sleep disorders, attacks, memory impairment, cognitive impairment, dementia, amnesia, delirium, obesity, eating disorder, appetite disorder, hyperphagia, bulimia, cibophobia, diabetes, cardiovascular diseases, hypertension, dyslipidemia, myocardial infarction, movement disorder (such as Parkinson's disease, epilepsy, convulsion or tremor), drug abuse, drug addiction or sexual dysfunction, based on a melanin-concentrating hormone receptor (MCH receptor) antagonistic action. SOLUTION A compound, a pharmaceutically acceptable salt or a hydrate thereof represented by the formula (I). 

7-piperidinoalkyl-3, 4-Dihydroquinolone derivative

A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a preventive or a remedy for allergic diseases such as asthma, atopic dermatitis and allergic rhinitis.

Isoquinoline derivative

Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).

Macrolide derivatives

[Object]: To provide a compound having a novel structure effective againstand erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against, erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.

10a-Azalide compound

Growing community of inventors

Tokyo, Japan

Madoka Kawamura